278 related articles for article (PubMed ID: 14690607)
1. Mechanism of SMRT corepressor recruitment by the BCL6 BTB domain.
Ahmad KF; Melnick A; Lax S; Bouchard D; Liu J; Kiang CL; Mayer S; Takahashi S; Licht JD; Privé GG
Mol Cell; 2003 Dec; 12(6):1551-64. PubMed ID: 14690607
[TBL] [Abstract][Full Text] [Related]
2. The BCL-6 POZ domain and other POZ domains interact with the co-repressors N-CoR and SMRT.
Huynh KD; Bardwell VJ
Oncogene; 1998 Nov; 17(19):2473-84. PubMed ID: 9824158
[TBL] [Abstract][Full Text] [Related]
3. Corepressor SMRT binds the BTB/POZ repressing domain of the LAZ3/BCL6 oncoprotein.
Dhordain P; Albagli O; Lin RJ; Ansieau S; Quief S; Leutz A; Kerckaert JP; Evans RM; Leprince D
Proc Natl Acad Sci U S A; 1997 Sep; 94(20):10762-7. PubMed ID: 9380707
[TBL] [Abstract][Full Text] [Related]
4. Structure of a BCOR corepressor peptide in complex with the BCL6 BTB domain dimer.
Ghetu AF; Corcoran CM; Cerchietti L; Bardwell VJ; Melnick A; Privé GG
Mol Cell; 2008 Feb; 29(3):384-91. PubMed ID: 18280243
[TBL] [Abstract][Full Text] [Related]
5. Recruitment of SMRT/N-CoR-mSin3A-HDAC-repressing complexes is not a general mechanism for BTB/POZ transcriptional repressors: the case of HIC-1 and gammaFBP-B.
Deltour S; Guerardel C; Leprince D
Proc Natl Acad Sci U S A; 1999 Dec; 96(26):14831-6. PubMed ID: 10611298
[TBL] [Abstract][Full Text] [Related]
6. Critical residues within the BTB domain of PLZF and Bcl-6 modulate interaction with corepressors.
Melnick A; Carlile G; Ahmad KF; Kiang CL; Corcoran C; Bardwell V; Prive GG; Licht JD
Mol Cell Biol; 2002 Mar; 22(6):1804-18. PubMed ID: 11865059
[TBL] [Abstract][Full Text] [Related]
7. The LAZ3/BCL6 oncogene encodes a sequence-specific transcriptional inhibitor: a novel function for the BTB/POZ domain as an autonomous repressing domain.
Deweindt C; Albagli O; Bernardin F; Dhordain P; Quief S; Lantoine D; Kerckaert JP; Leprince D
Cell Growth Differ; 1995 Dec; 6(12):1495-503. PubMed ID: 9019154
[TBL] [Abstract][Full Text] [Related]
8. The LAZ3(BCL-6) oncoprotein recruits a SMRT/mSIN3A/histone deacetylase containing complex to mediate transcriptional repression.
Dhordain P; Lin RJ; Quief S; Lantoine D; Kerckaert JP; Evans RM; Albagli O
Nucleic Acids Res; 1998 Oct; 26(20):4645-51. PubMed ID: 9753732
[TBL] [Abstract][Full Text] [Related]
9. Acetylation inactivates the transcriptional repressor BCL6.
Bereshchenko OR; Gu W; Dalla-Favera R
Nat Genet; 2002 Dec; 32(4):606-13. PubMed ID: 12402037
[TBL] [Abstract][Full Text] [Related]
10. Specific peptide interference reveals BCL6 transcriptional and oncogenic mechanisms in B-cell lymphoma cells.
Polo JM; Dell'Oso T; Ranuncolo SM; Cerchietti L; Beck D; Da Silva GF; Prive GG; Licht JD; Melnick A
Nat Med; 2004 Dec; 10(12):1329-35. PubMed ID: 15531890
[TBL] [Abstract][Full Text] [Related]
11. Crystal structure of the BTB domain from the LRF/ZBTB7 transcriptional regulator.
Stogios PJ; Chen L; Privé GG
Protein Sci; 2007 Feb; 16(2):336-42. PubMed ID: 17189472
[TBL] [Abstract][Full Text] [Related]
12. Class II histone deacetylases are directly recruited by BCL6 transcriptional repressor.
Lemercier C; Brocard MP; Puvion-Dutilleul F; Kao HY; Albagli O; Khochbin S
J Biol Chem; 2002 Jun; 277(24):22045-52. PubMed ID: 11929873
[TBL] [Abstract][Full Text] [Related]
13. The ansamycin antibiotic, rifamycin SV, inhibits BCL6 transcriptional repression and forms a complex with the BCL6-BTB/POZ domain.
Evans SE; Goult BT; Fairall L; Jamieson AG; Ko Ferrigno P; Ford R; Schwabe JW; Wagner SD
PLoS One; 2014; 9(3):e90889. PubMed ID: 24595451
[TBL] [Abstract][Full Text] [Related]
14. Point mutations in BCL6 DNA-binding domain reveal distinct roles for the six zinc fingers.
Mascle X; Albagli O; Lemercier C
Biochem Biophys Res Commun; 2003 Jan; 300(2):391-6. PubMed ID: 12504096
[TBL] [Abstract][Full Text] [Related]
15. BAZF, a novel Bcl6 homolog, functions as a transcriptional repressor.
Okabe S; Fukuda T; Ishibashi K; Kojima S; Okada S; Hatano M; Ebara M; Saisho H; Tokuhisa T
Mol Cell Biol; 1998 Jul; 18(7):4235-44. PubMed ID: 9632807
[TBL] [Abstract][Full Text] [Related]
16. BCoR, a novel corepressor involved in BCL-6 repression.
Huynh KD; Fischle W; Verdin E; Bardwell VJ
Genes Dev; 2000 Jul; 14(14):1810-23. PubMed ID: 10898795
[TBL] [Abstract][Full Text] [Related]
17. Components of the SMRT corepressor complex exhibit distinctive interactions with the POZ domain oncoproteins PLZF, PLZF-RARalpha, and BCL-6.
Wong CW; Privalsky ML
J Biol Chem; 1998 Oct; 273(42):27695-702. PubMed ID: 9765306
[TBL] [Abstract][Full Text] [Related]
18. Molecular dynamics analysis of the interaction between the human BCL6 BTB domain and its SMRT, NcoR and BCOR corepressors: the quest for a consensus dynamic pharmacophore.
Granadino-Roldán JM; Obiol-Pardo C; Pinto M; Garzón A; Rubio-Martínez J
J Mol Graph Model; 2014 May; 50():142-51. PubMed ID: 24793055
[TBL] [Abstract][Full Text] [Related]
19. Oligomerization of ETO is obligatory for corepressor interaction.
Zhang J; Hug BA; Huang EY; Chen CW; Gelmetti V; Maccarana M; Minucci S; Pelicci PG; Lazar MA
Mol Cell Biol; 2001 Jan; 21(1):156-63. PubMed ID: 11113190
[TBL] [Abstract][Full Text] [Related]
20. BCL6 programs lymphoma cells for survival and differentiation through distinct biochemical mechanisms.
Parekh S; Polo JM; Shaknovich R; Juszczynski P; Lev P; Ranuncolo SM; Yin Y; Klein U; Cattoretti G; Dalla Favera R; Shipp MA; Melnick A
Blood; 2007 Sep; 110(6):2067-74. PubMed ID: 17545502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
